Fulcrum Therapeutics Stock Price on November 29, 2024
| FULC Stock | USD 3.85 0.10 2.53% |
Below is the normalized historical share price chart for Fulcrum Therapeutics extending back to July 18, 2019. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Fulcrum Therapeutics stands at 3.85, as last reported on the 1st of December, with the highest price reaching 3.99 and the lowest price hitting 3.81 during the day.
If you're considering investing in Fulcrum Stock, it is important to understand the factors that can impact its price. Fulcrum Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0604, which denotes the company had a -0.0604% return per unit of risk over the last 3 months. Fulcrum Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Fulcrum Therapeutics' Variance of 77.91, mean deviation of 4.22, and Standard Deviation of 8.83 to check the risk estimate we provide.
At present, Fulcrum Therapeutics' Stock Based Compensation To Revenue is projected to increase slightly based on the last few years of reporting. . At present, Fulcrum Therapeutics' Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting. The current year's Price Sales Ratio is expected to grow to 154.91, whereas Price Earnings Ratio is forecasted to decline to (4.46). Fulcrum Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 18th of July 2019 | 200 Day MA 7.0366 | 50 Day MA 3.4314 | Beta 2.235 |
Fulcrum |
Sharpe Ratio = -0.0604
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FULC |
Estimated Market Risk
| 8.94 actual daily | 79 79% of assets are less volatile |
Expected Return
| -0.54 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fulcrum Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fulcrum Therapeutics by adding Fulcrum Therapeutics to a well-diversified portfolio.
Price Book 0.8071 | Enterprise Value Ebitda (3.09) | Price Sales 2.61 | Shares Float 40.4 M | Wall Street Target Price 5.2857 |
Related Headline
Crinetics Pharmaceuticals Headline on 29th of November 2024
Insider Selling Crinetics Pharmaceuticals, Inc. COO Sells 50... by thelincolnianonline.com
Crinetics Pharmaceuticals, Inc. COO Jeff E. Knight sold 501 shares of Crinetics Pharmaceuticals stock in a transaction on Friday, November 22nd. The stock was sold at an average price of 56.52, for a total transaction of 28,316.52. Following the completion of the transaction, the chief operating officer now owns 51,653
Fulcrum Therapeutics Valuation on November 29, 2024
It is possible to determine the worth of Fulcrum Therapeutics on a given historical date. On November 29, 2024 Fulcrum was worth 3.93 at the beginning of the trading date compared to the closed value of 3.85. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Fulcrum Therapeutics stock. Still, in general, we apply an absolute valuation method to find Fulcrum Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Fulcrum Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Fulcrum Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 3.57 | 4.08 | 3.57 | 3.95 | 1,008,852 | |
11/29/2024 | 3.93 | 3.99 | 3.81 | 3.85 | 527,111 |
| 3.93 | 3.99 | 3.81 | 3.85 | 0.00 |
| Backtest Fulcrum Therapeutics | | | Fulcrum Therapeutics History | | | Fulcrum Therapeutics Valuation | Previous | Next |
Fulcrum Therapeutics Trading Date Momentum on November 29, 2024
| On December 01 2024 Fulcrum Therapeutics was traded for 3.85 at the closing time. The top price for the day was 3.99 and the lowest listed price was 3.81 . There was no trading activity during the period 0.0. Lack of trading volume on December 1, 2024 did not affect price variability. The overall trading delta against the current closing price is 2.08% . |
Fulcrum Therapeutics Fundamentals Correlations and Trends
By evaluating Fulcrum Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Fulcrum Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Fulcrum financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Fulcrum Therapeutics Stock history
Fulcrum Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Fulcrum is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Fulcrum Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Fulcrum Therapeutics stock prices may prove useful in developing a viable investing in Fulcrum Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 61.3 M | 32.4 M | |
| Net Loss | -98.9 M | -103.8 M |
Fulcrum Therapeutics Quarterly Net Working Capital |
|
Fulcrum Therapeutics Stock Technical Analysis
Fulcrum Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Fulcrum Therapeutics Period Price Range
Low | December 1, 2024
| High |
0.00 | 0.00 |
Fulcrum Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Fulcrum Therapeutics December 1, 2024 Market Strength
Market strength indicators help investors to evaluate how Fulcrum Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Fulcrum Therapeutics shares will generate the highest return on investment. By undertsting and applying Fulcrum Therapeutics stock market strength indicators, traders can identify Fulcrum Therapeutics entry and exit signals to maximize returns
Fulcrum Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Fulcrum Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Fulcrum Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Fulcrum to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (2.14) | |||
| Treynor Ratio | (0.79) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |